WO2001034137A3 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
WO2001034137A3
WO2001034137A3 PCT/US2000/031039 US0031039W WO0134137A3 WO 2001034137 A3 WO2001034137 A3 WO 2001034137A3 US 0031039 W US0031039 W US 0031039W WO 0134137 A3 WO0134137 A3 WO 0134137A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
oncolytic
combinations
oncolytic combinations
Prior art date
Application number
PCT/US2000/031039
Other languages
French (fr)
Other versions
WO2001034137A2 (en
Inventor
Jerome Herbert Fleisch
Roger Stuart Benjamin
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Original Assignee
Lilly Co Eli
Jerome Herbert Fleisch
Roger Stuart Benjamin
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002391416A priority Critical patent/CA2391416A1/en
Priority to AU15990/01A priority patent/AU778829B2/en
Priority to SK649-2002A priority patent/SK6492002A3/en
Priority to IL14857900A priority patent/IL148579A0/en
Priority to EA200200545A priority patent/EA200200545A1/en
Priority to KR1020027006027A priority patent/KR20020069512A/en
Priority to MXPA02004733A priority patent/MXPA02004733A/en
Priority to BR0015490-3A priority patent/BR0015490A/en
Application filed by Lilly Co Eli, Jerome Herbert Fleisch, Roger Stuart Benjamin, Jason Scott Sawyer, Beverly Ann Teicher, Douglas Wade Beight, Edward C R Smith, William Thomas Mcmillen filed Critical Lilly Co Eli
Priority to EP00978535A priority patent/EP1231938A2/en
Priority to NZ517667A priority patent/NZ517667A/en
Priority to JP2001536137A priority patent/JP2003513916A/en
Priority to PL00355172A priority patent/PL355172A1/en
Priority to HU0204449A priority patent/HUP0204449A3/en
Publication of WO2001034137A2 publication Critical patent/WO2001034137A2/en
Publication of WO2001034137A3 publication Critical patent/WO2001034137A3/en
Priority to NO20022245A priority patent/NO20022245L/en
Priority to HK03100750.7A priority patent/HK1050132A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Leukotriene (LTB4) antagonists enhance the effectiveness of 2',2'-difluoronucleoside anti-cancer agents.
PCT/US2000/031039 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer WO2001034137A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP00978535A EP1231938A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
AU15990/01A AU778829B2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
NZ517667A NZ517667A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
EA200200545A EA200200545A1 (en) 1999-11-11 2000-11-09 ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
KR1020027006027A KR20020069512A (en) 1999-11-11 2000-11-09 Oncolytic Combinations for the Treatment of Cancer
MXPA02004733A MXPA02004733A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer.
BR0015490-3A BR0015490A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
CA002391416A CA2391416A1 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
SK649-2002A SK6492002A3 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
IL14857900A IL148579A0 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
JP2001536137A JP2003513916A (en) 1999-11-11 2000-11-09 Oncolytic compounds for cancer treatment
PL00355172A PL355172A1 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
HU0204449A HUP0204449A3 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
NO20022245A NO20022245L (en) 1999-11-11 2002-05-10 Oncolytic combinations for the treatment of cancer
HK03100750.7A HK1050132A1 (en) 1999-11-11 2003-01-29 Oncolytic combinations for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11
US60/164,786 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034137A2 WO2001034137A2 (en) 2001-05-17
WO2001034137A3 true WO2001034137A3 (en) 2002-02-14

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031039 WO2001034137A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (en)
JP (1) JP2003513916A (en)
KR (1) KR20020069512A (en)
CN (1) CN1390139A (en)
AR (1) AR032432A1 (en)
AU (1) AU778829B2 (en)
BR (1) BR0015490A (en)
CA (1) CA2391416A1 (en)
CZ (1) CZ20021551A3 (en)
EA (1) EA200200545A1 (en)
HK (1) HK1050132A1 (en)
HU (1) HUP0204449A3 (en)
IL (1) IL148579A0 (en)
MX (1) MXPA02004733A (en)
NO (1) NO20022245L (en)
NZ (1) NZ517667A (en)
PE (1) PE20010701A1 (en)
PL (1) PL355172A1 (en)
SK (1) SK6492002A3 (en)
TR (1) TR200201245T2 (en)
WO (1) WO2001034137A2 (en)
ZA (1) ZA200202822B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
KR20030019372A (en) * 2000-05-09 2003-03-06 크레이톤 유니버시티 Methods for inhibiting proliferation and inducing apoptosis in cancer cells
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP4981662B2 (en) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー New compounds, their preparation and use
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CN1302782C (en) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 Jixitabing hydrochloride solution type injection agent
ES2449618T3 (en) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Phenoxyacetic acids as activators of PPAR-delta
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US8044236B2 (en) 2006-10-12 2011-10-25 Institute Of Medicinal Molecular Design, Inc. Carboxilic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (en) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclic compounds as pesticides
WO2014067962A1 (en) 2012-10-31 2014-05-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
CN103319466B (en) * 2013-07-04 2016-03-16 郑州大学 Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
WO2001034137A2 (en) 2001-05-17
CA2391416A1 (en) 2001-05-17
AR032432A1 (en) 2003-11-12
BR0015490A (en) 2002-07-09
NO20022245L (en) 2002-07-09
HUP0204449A2 (en) 2003-04-28
PL355172A1 (en) 2004-04-05
HK1050132A1 (en) 2003-06-13
CN1390139A (en) 2003-01-08
NO20022245D0 (en) 2002-05-10
JP2003513916A (en) 2003-04-15
IL148579A0 (en) 2002-09-12
AU1599001A (en) 2001-06-06
TR200201245T2 (en) 2004-08-23
SK6492002A3 (en) 2003-09-11
AU778829B2 (en) 2004-12-23
KR20020069512A (en) 2002-09-04
NZ517667A (en) 2004-05-28
EA200200545A1 (en) 2002-12-26
HUP0204449A3 (en) 2006-02-28
ZA200202822B (en) 2003-09-23
CZ20021551A3 (en) 2003-02-12
PE20010701A1 (en) 2001-07-07
MXPA02004733A (en) 2002-08-30
EP1231938A2 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
WO2001034137A3 (en) Oncolytic combinations for the treatment of cancer
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
AU7834500A (en) Well treatment fluids comprising mixed aldehydes
ZA200006042B (en) Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections.
HK1051193A1 (en) (1,4')-Bipiperidine compounds.
ZA200202461B (en) Compounds for the treatment of ischemia.
DZ3165A1 (en) Food or pharmaceutical composition used to prevent or treat hyperoxaluria.
ZA993345B (en) Nefazodone dosage form.
TR199800436A3 (en) The use of primidine derivatives for cancer prevention.
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
ZA200204325B (en) Area Denial.
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
ZA200003236B (en) Combination therapy for the treatment of migraine.
ITRE990028A0 (en) CHELATED FOOD SUPPLEMENT FOR AGRO-ZOOTECHNICAL USE, AND METHOD FOR OBTAINING THE SAME.
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200203166B (en) Treatment of cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148579

Country of ref document: IL

Ref document number: 517667

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 15990/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10110804

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/559/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2002-1551

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20020402A

Country of ref document: HR

Ref document number: 2002/01245

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2001 536137

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004733

Country of ref document: MX

Ref document number: 6492002

Country of ref document: SK

Ref document number: 008155798

Country of ref document: CN

Ref document number: 1020027006027

Country of ref document: KR

Ref document number: 1200200411

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2391416

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000978535

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200200545

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2000978535

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027006027

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1551

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 517667

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517667

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000978535

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 15990/01

Country of ref document: AU